自2019年12月开始，COVID-19疾病在全球范围内开始传播，至今仍持续。在早期阶段，该疾病可能与高的D-二聚体水平有关，该水平可指示凝血途径和血栓形成的激活情况，受到一些潜在疾病的影响，包括糖尿病、中风、癌症和妊娠，同时也可能与慢性阻塞性肺疾病（COPD）有关。本文旨在分析COVID-19患者D-二聚体水平，因为D-二聚体水平是检测COVID-19严重程度和预后的指标之一。根据本研究结果，在疾病发作时的D-二聚体水平以及纤维蛋白原浓度都较高，而较高的D-二聚体水平与糟糕的预后相关，可能会使D-二聚体水平增加3至4倍。研究显示76%的患者在≥1次D-二聚体测量中存在升高，并且比正常D-二聚体水平的患者更容易患重症。D-二聚体水平超过2000 ng/mL时不良结果的发生率增加，其中死亡风险最高为47%，血栓事件发生率为37.8%，重症疾病发生率为66%。研究还发现，糖尿病和COPD与COVID-19的死亡风险最相关。因此，必须从早期开始测量D-二聚体水平和凝血参数，并注意可能有助于控制和管理COVID-19的合并症。版权所有©2022年国家结核病和肺部疾病研究所。

COVID-19 disease began to spread all around the world in December 2019 until now; and in the early stage it may be related to high D-dimer level that indicates coagulation pathways and thrombosis activation that can be affected by some underlying diseases including diabetes, stroke, cancer, and pregnancy and it also can be associated with Chronic obstructive pulmonary disease (COPD). The aim of this article was to analyze D-dimer levels in COVID-19 patients, as D-dimer level is one of the measures to detect the severity and outcomes of COVID-19. According to the results of this study, there is a higher level of D-dimer as well as concentrations of fibrinogen in the disease onset and it seems that the poor prognosis is linked to a 3 to 4-fold increase in D-dimer levels. It is also shown that 76% of the patients with ≥1 D-dimer measurement, had elevated D-dimer and were more likely to have critical illness than those with normal D-dimer. There was an increase in the rates of adverse outcomes with higher D-dimer of more than 2000 ng/mL and it is associated with the highest risk of death at 47%, thrombotic event at 37.8%, and critical illness at 66%. It also found that diabetes and COPD had the strongest association with death in COVID-19. So, it is necessary to measure the D-dimer levels and parameters of coagulation from the beginning as well as pay attention to comorbidities that can help control and management of COVID-19 disease.Copyright© 2022 National Research Institute of Tuberculosis and Lung Disease.